PL3761982T3 - Zastosowanie nalfurafiny w leczeniu chorób demielinizacyjnych - Google Patents

Zastosowanie nalfurafiny w leczeniu chorób demielinizacyjnych

Info

Publication number
PL3761982T3
PL3761982T3 PL19765122.7T PL19765122T PL3761982T3 PL 3761982 T3 PL3761982 T3 PL 3761982T3 PL 19765122 T PL19765122 T PL 19765122T PL 3761982 T3 PL3761982 T3 PL 3761982T3
Authority
PL
Poland
Prior art keywords
nalfurafine
treatment
demyelinating diseases
demyelinating
diseases
Prior art date
Application number
PL19765122.7T
Other languages
English (en)
Inventor
Bronwyn Maree Kivell
Anne Camille La Flamme
Thomas Edward Prisinzano
Original Assignee
Victoria Link Ltd
University Of Kansas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2018900754A external-priority patent/AU2018900754A0/en
Application filed by Victoria Link Ltd, University Of Kansas filed Critical Victoria Link Ltd
Publication of PL3761982T3 publication Critical patent/PL3761982T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Neurosurgery (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PL19765122.7T 2018-03-08 2019-03-07 Zastosowanie nalfurafiny w leczeniu chorób demielinizacyjnych PL3761982T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AU2018900754A AU2018900754A0 (en) 2018-03-08 Treatment of demyelinating diseases
PCT/IB2019/051870 WO2019171333A1 (en) 2018-03-08 2019-03-07 Treatment of demyelinating diseases

Publications (1)

Publication Number Publication Date
PL3761982T3 true PL3761982T3 (pl) 2025-03-17

Family

ID=67846938

Family Applications (1)

Application Number Title Priority Date Filing Date
PL19765122.7T PL3761982T3 (pl) 2018-03-08 2019-03-07 Zastosowanie nalfurafiny w leczeniu chorób demielinizacyjnych

Country Status (11)

Country Link
US (3) US20210015813A1 (pl)
EP (1) EP3761982B1 (pl)
AU (1) AU2019229892B2 (pl)
CA (1) CA3091752A1 (pl)
DK (1) DK3761982T3 (pl)
ES (1) ES3006014T3 (pl)
FI (1) FI3761982T3 (pl)
HU (1) HUE069820T2 (pl)
PL (1) PL3761982T3 (pl)
PT (1) PT3761982T (pl)
WO (1) WO2019171333A1 (pl)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3761982B1 (en) 2018-03-08 2024-10-09 Victoria Link Ltd Use of nalfurafine for the treatment of demyelinating diseases
WO2021186035A1 (en) 2020-03-20 2021-09-23 Medizinische Universität Wien Cyclotides in combination with kappa opioid receptor ligands for ms therapy
WO2024229174A1 (en) * 2023-05-02 2024-11-07 Cognito Therapeutics, Inc. Gamma stimulation and neuromodulator combination therapy

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4994466A (en) 1990-06-14 1991-02-19 Baker Cummins Pharmaceuticals, Inc. Method of treatment for multiple sclerosis
CA2105072C (en) 1992-01-23 1998-07-28 Hiroshi Nagase Morphinan derivative and its pharmaceutical applications
JP3123080B2 (ja) 1995-09-26 2001-01-09 東レ株式会社 「インドール誘導体およびその医薬用途」
EP1327444B1 (en) 1996-11-25 2005-03-23 Toray Industries, Inc. Antipruritic agent
US6440987B1 (en) 1996-11-25 2002-08-27 Toray Industries, Inc. Antipruritic
TWI285644B (en) 1997-07-11 2007-08-21 Toray Industries A stable pharmaceutical composition containing a derivative of 4,5-epoxymorphinan and a water-soluble antioxidant, an oil-soluble antioxidant, a synergist, a sugar and a surfactant
JP2000053572A (ja) 1998-08-11 2000-02-22 Toray Ind Inc ＯＲＬ１（ｏｐｉｏｉｄ ｏｒｐｈａｎ）受容体拮抗薬
WO2001014383A1 (en) 1999-08-24 2001-03-01 Toray Industries, Inc. Remedies for neuropathic pain and model animals of neuropathic pain
JP2001163784A (ja) 1999-12-06 2001-06-19 Toray Ind Inc 角膜または結膜用止痒剤
JP4370683B2 (ja) 2000-05-08 2009-11-25 東レ株式会社 そう痒疾患の検査方法
KR20030053530A (ko) 2000-11-22 2003-06-28 도레이 가부시끼가이샤 인돌 유도체 및 그 의약용도
CA2442423C (en) 2001-03-30 2009-11-03 Toray Industries, Inc. Therapeutic drug for psychoneurotic disorders
JP2002332284A (ja) 2001-05-08 2002-11-22 Toray Ind Inc 二価性モルヒナン誘導体およびその医薬用途
JP4957489B2 (ja) 2002-10-09 2012-06-20 東レ株式会社 含窒素環状置換基を有するモルヒナン誘導体またはその薬理学的に許容される酸付加塩を含有する医薬
US7320984B2 (en) 2002-10-09 2008-01-22 Toray Industries, Inc. Remedies or preventives for urinary frequency or urinary incontinence and morphinan derivatives having nitrogen-containing heterocyclic group
ATE414516T1 (de) 2004-03-30 2008-12-15 Toray Industries Morphinanderivate als mittel gegen juckreiz
US20060069086A1 (en) * 2004-09-23 2006-03-30 Alexander Michalow Methods for regulating neurotransmitter systems by inducing counteradaptations
AR053098A1 (es) 2004-11-04 2007-04-25 Toray Industries Analgesico derivado de morfinano
CA2604071C (en) 2005-03-10 2013-10-08 Toray Industries, Inc. Antipruritic agent for pruritus caused by multiple sclerosis
BRPI0608671B1 (pt) 2005-04-06 2022-07-19 Toray Industries, Inc Processos para produzir um cristal de forma a de cloridrato de 17-ciclopropilmetil-3,14 b-diidróxi-4,5a-epóxi-6b-[n-metil-trans-3-(3-furil)-acril amido]-morfinano
KR20080065664A (ko) 2005-11-09 2008-07-14 도레이 가부시끼가이샤 기능성 장장해의 치료 또는 예방제
US8106065B2 (en) 2005-12-21 2012-01-31 Toray Industries, Inc. Antitussive agent
WO2008024490A2 (en) 2006-08-24 2008-02-28 Theraquest Biosciences, Inc. Oral pharmaceutical formulations of abuse deterrent cannabinoids and method of use
CA2685126C (en) 2007-04-24 2015-04-14 Toray Industries, Inc. Therapeutic or prophylactic agent for dyskinesia
KR101491656B1 (ko) 2007-04-26 2015-02-09 도레이 카부시키가이샤 4,5-에폭시모르피난 유도체를 함유하는 안정한 고형 제제
KR101173509B1 (ko) 2007-10-05 2012-08-14 도레이 카부시키가이샤 모르피난 유도체 또는 그 약리학적으로 허용되는 산부가염을 유효 성분으로 하는 피부 성상 개선 치료약
JP5252391B2 (ja) 2008-02-21 2013-07-31 学校法人北里研究所 オキサビシクロ［２．２．２］オクタンを有するモルヒナン誘導体およびその医薬用途
DK2356989T3 (en) 2008-10-24 2018-05-07 Toray Industries Stable tablet containing 4,5-epoxymorphinane derivative
TWI455733B (zh) 2009-03-30 2014-10-11 Toray Industries 口腔內崩壞性被覆錠劑
JP2011074018A (ja) 2009-09-30 2011-04-14 Toray Ind Inc 線維筋痛症の治療剤又は予防剤
MY173491A (en) 2010-01-29 2020-01-29 Toray Industries Therapeutic or prophylactic agent for biliary tract diseases
WO2012105475A1 (ja) 2011-01-31 2012-08-09 東レ株式会社 悪液質の治療又は予防剤
DK2675893T3 (en) 2011-02-18 2019-04-15 Scripps Research Inst Directed differentiation of oligodendrocyte precursor cells into a myelinating cell fate
US9248128B2 (en) 2012-01-27 2016-02-02 New York University Method for enhancing remyelination using GLI1 inhibitors
US20150150935A1 (en) 2012-06-05 2015-06-04 Cara Therapeutics, Inc. Peripheral kappa receptor agonists for reducing pain and inflammation
CN102993125A (zh) 2012-09-25 2013-03-27 中国人民解放军第四军医大学 一种新的用于缺血心脏保护作用的κ-阿片受体激动剂
CN104919095B (zh) 2012-12-19 2017-06-30 加利福尼亚大学董事会 用于测定髓鞘形成的微柱阵列
JP6359014B2 (ja) 2013-08-21 2018-07-18 久光製薬株式会社 貼付剤
JP6306594B2 (ja) 2013-08-21 2018-04-04 久光製薬株式会社 貼付剤
JP6247118B2 (ja) 2014-03-05 2017-12-13 東海カプセル株式会社 カプセル充填組成物
JP2016155794A (ja) 2014-06-09 2016-09-01 富士カプセル株式会社 ナルフラフィン塩酸塩及びフィチン酸又はその塩を含有するカプセル製剤
CN105462930B (zh) 2014-06-24 2020-10-20 中国人民解放军军事医学科学院毒物药物研究所 一种筛选κ阿片受体激动剂的细胞模型及筛选方法
TW201707703A (zh) * 2015-06-04 2017-03-01 Tokai Capsule Co Ltd 軟膠囊劑
US10525015B2 (en) 2015-06-24 2020-01-07 University Of Tsukuba Nalfurafine-containing percutaneous absorption patch
WO2017049252A1 (en) 2015-09-17 2017-03-23 Switch Bio, Inc. Compositions and methods for treating neurological disorders
JPWO2017094337A1 (ja) 2015-12-04 2018-09-20 ニチバン株式会社 貼付剤
CN108883025A (zh) 2016-03-31 2018-11-23 日绊株式会社 贴剂产品
WO2017220431A1 (en) 2016-06-20 2017-12-28 Almirall, S.A. Fused pyrazole derivatives as jak inhibitors
JP2018048093A (ja) 2016-09-23 2018-03-29 東レ株式会社 モルヒナン誘導体及びその医薬用途
WO2018181920A1 (ja) 2017-03-31 2018-10-04 東レ株式会社 ナルフラフィンを含有する錠剤化された医薬組成物
WO2019171332A1 (en) 2018-03-08 2019-09-12 Victoria Link Ltd Treatment of demyelinating diseases
EP3761982B1 (en) 2018-03-08 2024-10-09 Victoria Link Ltd Use of nalfurafine for the treatment of demyelinating diseases

Also Published As

Publication number Publication date
WO2019171333A1 (en) 2019-09-12
CA3091752A1 (en) 2019-09-12
US20210015813A1 (en) 2021-01-21
US11324742B2 (en) 2022-05-10
AU2019229892B2 (en) 2025-01-30
RU2020128028A (ru) 2022-04-08
EP3761982B1 (en) 2024-10-09
US12318380B2 (en) 2025-06-03
DK3761982T3 (da) 2025-01-02
EP3761982A1 (en) 2021-01-13
PT3761982T (pt) 2024-12-30
US20210069179A1 (en) 2021-03-11
EP3761982A4 (en) 2021-12-15
US20230096920A1 (en) 2023-03-30
ES3006014T3 (en) 2025-03-17
HUE069820T2 (hu) 2025-04-28
AU2019229892A1 (en) 2020-09-03
FI3761982T3 (fi) 2025-01-03

Similar Documents

Publication Publication Date Title
IL276398B1 (en) Combination therapy for mastocytosis
ZA201908165B (en) Compounds for the prevention and treatment of diseases and the use thereof
PL3672954T3 (pl) Związki, ich sole i ich zastosowanie w leczeniu chorób
IL279260A (en) KDM1A inhibitors for the treatment of diseases
SG11202006374VA (en) Treatment of demyelinating diseases
ZA201906213B (en) Compounds and methods for the treatment of parasitic diseases
IL283948A (en) Methods for treating depression
IL282643A (en) Soft combinations for the treatment of hematological diseases
IL276482A (en) Compounds for pain management
GB201805100D0 (en) Treatment of sarcopenic diseases
EP3744347A4 (en) COMPOSITION FOR USE IN THE TREATMENT OF SKIN DISEASES
PL3603621T3 (pl) Liposomy do leczenia chorób oczu
SG11202103141YA (en) Combination therapy for the treatment of cancer
LT3924340T (lt) Indazolil-izoksazolo dariniai, skirti ligų, tokių kaip vėžys, gydymui
IL284162A (en) Integrated healing for cancer treatment
PL3761982T3 (pl) Zastosowanie nalfurafiny w leczeniu chorób demielinizacyjnych
IL282360A (en) Treatment for neurological diseases
PT3619204T (pt) Compostos para o tratamento de doenças respiratórias
IL281782A (en) Drug combination for cancer treatment
HK40061035A (en) Novel compounds for the treatment of respiratory diseases
AU2018904241A0 (en) Novel compounds for the treatment of respiratory diseases
AU2018900753A0 (en) Treatment of demyelinating diseases
AU2018900754A0 (en) Treatment of demyelinating diseases
GB201909438D0 (en) Treatment of diseases
AU2017901647A0 (en) Compounds for the treatment of respiratory diseases